1. Enthesitis in Psoriatic Arthritis: Disease, Diagnosis and Decisions

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Program Overview

4. Introduction

5. Overview of PsA Heterogeneity and Disease Domains

6. Typical Presentations of PsA

7. Challenges/Barriers in Accurate and Timely Diagnosis of PsA
Challenges/Barriers in Accurate and Timely Diagnosis of PsA? --Expert Perspective

8. PsA Eludes Early Diagnosis

9. Patients have Delays and Misdiagnoses Before they Receive a PsA Diagnosis

10. Key Factors for a Dermatologist to Overcome Barriers in PsA Diagnosis

11. When Does a Dermatologist Refer to a Rheumatologist?

12. Combined Clinics

13. Evaluating patients with psoriasis for signs and symptoms of PsA

14. Screening Tools: Questionnaires

15. Screening Tools: Questionnaires (II)

16. What Should a Rheumatologist Consider to Overcome Barriers in PsA Diagnosis?

17. Other Aspects of Optimal Management Between Rheumatologists and Dermatologists

18. Impact of a Delay in PsA Diagnosis, Why is Early Diagnosis Important?

19. Delay in Diagnosis > 6 Months Leads to Poorer Outcomes in PsA

20. What do we know about Enthesitis in PsA Disease?

21. Value of Ultrasound for Early PsA Diagnosis

22. Enthesitis vs Synovitis

23. Which Techniques are used to Identify/Assess Enthesitis?

24. What is the Immunopathogenesis of Enthesitis?

25. What Should a Dermatologist Know about Enthesitis? –Expert Perspective

26. What Treatments are Available for PsA?

27. Etanercept and Methotrexate in Patients with Psoriatic Arthritis: SEAM - PsA

28. Enthesitis Outcomes in RCT in PsA: TNFi

29. Enthesitis Outcomes with Ixekizumab (IL-17i)

30. Enthesitis Outcomes with Secukinumab (IL-17i)

31. FUTURE 5: Secukinumab Improved Resolution of Enthesitis in PsA Patients

32. Enthesitis Outcomes in RCT in PsA: IL-23i

33. Enthesitis Outcomes in RCT in PsA: PDE4i, T-cell I and JAKi

34. Recent and Upcoming Head-to-Head Trials Evaluating Enthesitis in PsA

35. Safety Considerations

36. Safety Considerations –Expert Perspective (II)

37. Concluding Remarks

38. Abbreviations

39. Abbreviations (cont)

40. Abbreviations (cont)